Operator

Hello, and welcome, everyone, joining The Oncology Institute First Quarter 2026 Earnings Call. [Operator Instructions] Please note this call is being recorded. [Operator Instructions]

It is now my pleasure to turn the meeting over to Minh Merchant, Chief Legal Officer. Please go ahead.

Minh Merchant
Chief Legal Officer

The press release announcing The Oncology Institute's results for the first quarter of 2026 are available at the Investors section of the company's website, theoncologyinstitute.com. A replay of this call will also be available at the company's website after the conclusion of this call.

Before we get started, I'd like to remind you of the company's safe harbor language included within the company's press release for the first quarter of 2026. Management may make forward-looking statements, including guidance and underlying assumptions. Forward-looking statements are based on expectations that involve risks and uncertainties that could cause actual results to differ materially. For a further discussion of risks related to our business, see our filings with the SEC.

This call will also discuss non-GAAP financial measures such as adjusted EBITDA and free cash flow. Reconciliation of these non-GAAP measures to the most comparable GAAP measures are included in the earnings release furnished to the SEC and available on our website.

Joining me on the call today are our CEO, Dan Virnich; and our CFO, Rob Carter. Following our prepared remarks, we'll open the call for your questions.